Truscreen Group Ltd
NZX:TRU
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| NZ |
|
Truscreen Group Ltd
NZX:TRU
|
12.7m NZD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
191.3B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172.7B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.6B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
133.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
115.8B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
46.4B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.8B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.7B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
39B USD |
Loading...
|
Market Distribution
| Min | -1 380.2% |
| 30th Percentile | 2.6% |
| Median | 8.5% |
| 70th Percentile | 15.6% |
| Max | 98.6% |
Other Profitability Ratios
Truscreen Group Ltd
Glance View
TruScreen Group Ltd. engages in the development, manufacture, and sale of cancer detection device and systems. The firm is engaged in the business of the development, manufacturing and sale of cancer detection devices and systems. Its cervical cancer screening device offers technology in cervical screening, providing detection of precancerous and cancerous cervical cells to help improve the health and well-being of women worldwide. Its real-time cervical cancer technology utilizes a digital wand, which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated algorithm framework is utilized to detect pre-cancerous change, or cervical intraepithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue. The product offers an approach to cervical screening, resolving ongoing issues with Pap smear (Pap tests), including failed samples, patient follow-up, patient discomfort and the need for supporting laboratory infrastructure.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Truscreen Group Ltd is -157.9%, which is below its 3-year median of -123.3%.
Over the last 3 years, Truscreen Group Ltd’s Operating Margin has increased from -180.9% to -157.9%. During this period, it reached a low of -180.9% on Aug 30, 2022 and a high of -83.7% on Sep 30, 2024.
